SUSAN G. KOMEN ANNOUNCES $26 MILLION INVESTMENT IN NEW RESEARCH TO FIND SOLUTIONS FOR AGGRESSIVE AND METASTATIC BREAST CANCERS, AND TO HELP COMMUNITIES MOST AT RISK
Michigan Researchers Receive $1,075,000 in Research Funding
DALLAS – Sept. 25, 2018 – Susan G. Komen®, the world’s leading breast cancer organization, today announced an additional investment of nearly $26 million to fund 62 new research projects that seek to answer some of the toughest questions facing breast cancer. This new funding is part of the organization’s efforts to reduce the number of breast cancer deaths in the U.S. by 50 percent by 2026 and brings its total research investment to $988 million to date – the largest nonprofit investment outside the U.S. government.
The grants include $1,075,000 in new funding for research at three institutions in Michigan, bringing Komen’s total research investment in Michigan to $29,377,633 since 1982.
“This year, Komen is investing in a number of areas that will help us achieve our bold goal and save lives. We are seeking answers to why our current drugs work for some patients, but not all, or why they work at first, but later become ineffective.” said Komen Chief Scientific Advisor, George Sledge, M.D., Chief of Oncology at Stanford University Department of Medicine. “We are also looking into aggressive forms of the disease like triple negative and inflammatory breast cancer, which tend to have poorer outcomes. By investigating novel techniques and therapies, we hope to bring new treatment options to patients.”
The newly announced grants will investigate critical areas in breast cancer research, including (but not limited to) projects focused on one or more of the following:
- Drug Resistance and Metastasis (40 grants, representing 70 percent of the grants awarded)
- Triple Negative Breast Cancer (23 grants)
- New Treatments (38 grants) such as Immunotherapies (9 grants)
- Health Disparities (8 grants)
This year, Komen’s competitive grant program for young investigators was entirely focused on drug resistance and metastatic disease. “Komen continues its long-standing investment in the next generation of scientists, to ensure that brilliant researchers whose careers are just beginning have funding to pursue their novel ideas,” said Komen Chief Scientific Advisor, Jennifer Pietenpol, Ph.D., Executive Vice President for Research and Director of the Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center. “We are proud that this investment includes opportunities for 23 innovative and inspired researchers to lead the way in making breast cancer discoveries that will improve care for all and help save lives.”
“More than 41,000 women and men will lose their lives to breast cancer this year alone. I lost my mother to the disease a few years back, and I myself have been treated for aggressive triple negative breast cancer. The idea that it could impact my daughters is unacceptable,” said Komen President and CEO Paula Schneider. “We all have a personal reason or passion that we support the fight against breast cancer, and we’re proud to invite people to support the work that means the most to them. It will take all of us working together to save lives and ultimately end this disease.”
Komen’s Investments in Michigan
Komen’s research program is funded in part by contributions from Komen’s nationwide Network of Affiliates, which directs a portion of funds raised locally to Komen’s national research program, while also investing in vital community programs that serve local women and men facing breast cancer.
Since 1996, Komen Michigan has funded $7,574,997 to community programs serving local women and men, while contributing $4,044,405 to Komen research.
“We are so thankful for the friends, family and neighbors that fight alongside us, helping to reduce the number of breast cancer deaths in Michigan, both on the ground and through research,” said Erica Bills, Executive Director, Komen Michigan.
In Michigan, Komen is granting to the following researchers:
- Komen Scholar Daniel Hayes, M.D., from the University of Michigan, will receive $200,000 to continue to use “liquid biopsies” to evaluate the circulating tumor cells in a patient’s blood stream, and inform treatment decisions about targeted therapies. Dr. Hayes and team will also refine their current technology for collecting the liquid biopsies.
- Komen Scholar Reshma Jagsi, M.D., D.Phil., from The University of Michigan, will receive $600,000 to investigate the use of drugs called PARP inhibitors, in combination with radiation, to treat inflammatory breast cancer (IBC), a rare but aggressive form of breast cancer. This project will identify the biomarkers that could predict therapy response and lead to improving precision treatment for women with IBC.
- Tsu-Yin Wu, Ph.D. RN, FAAN, from the University of Michigan, Lansing, will receive $175,000 to support the Evidence-Based Sustainable Strategies for Early Diagnosis of Breast Cancer in China research study. This study will determine whether an educational intervention (vs. nonintervention) can increase the number of women that are screened through public programs and reduce the breast cancer stage at diagnosis. The study builds on previous Komen work in China, and aims to educate patients as well as train primary health care providers.
- Karin List, Ph.D., from Wayne State University will receive $100,000 to continue research to test a new drug that inhibits matriptase – a protein-cutting enzyme that helps tumors spread to distant sites – to determine if the drug can stop Inflammatory Breast Cancer (IBC) from growing or spreading. She will also test whether the drug can be combined with existing therapies to overcome drug resistance. Dr. List will use patient samples to develop new mouse models of IBC to test this treatment, which will provide a valuable resource for the IBC research community to test new therapies.
Research has been a cornerstone of Komen’s work since opening its doors in 1982. Komen also works to inspire action through advocacy and public policy, to mobilize communities through support services and opportunities to make a local impact, and provide the care that patients need (including screening, diagnostics, treatment and navigation).
About Komen Michigan
Komen Michigan is committed to saving lives and reducing breast cancer deaths in Michigan. Through targeted, culturally-relevant education programs, screenings, diagnostics, transportation, survivor support programs and events like Race for the Cure®, Komen Michigan has touched nearly 59,000 lives in Michigan in 2017 alone. Over the last 20 years, Komen Michigan has funded $12 million in community breast health programs and support across 24 counties, filling the gap for much-needed services. Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50% in the U.S. by 2026. Contact at (616) 752-8262 or www.komenmichigan.org.
About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026. Since its founding in 1982, Komen has funded more than $988 million in research and provided more than $2.2 billion in funding to screening, education, treatment and psychosocial support programs serving millions of people in more than 60 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. That promise has become Komen’s promise to all people facing breast cancer. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.
Grants are contingent upon signed and executed contracts with Komen.